

VASOOCCLUSIVE PAIN CRISIS IN SICKLE CELL DISEASE

Amber Schilling, PharmD

Objectives

- Describe the clinical presentation of a vasoocclusive pain crisis in sickle cell disease.
- List treatment modalities for vasoocclusive pain crisis.

Definitions

- Sickle Cell Disease (SCD)^{1,2}
 - An inherited (genetic) disorder where both genes encoding for hemoglobin production are mutant, producing red blood cells that are abnormally shaped
 - Abnormal shape = sickle (crescent)
 - Results in RBC hemolysis (anemia) and multiple organ complications
- Vasocclusive Pain Crisis^{1,2} (AKA Acute painful episode)
 - Hallmark clinical presentation of SCD
 - An episode of acute pain caused tissue hypoxia (infarction) from sickled RBC obstructing capillary blood flow
 - Most commonly involves the bones, liver, spleen, brain, lungs, and genitals
 - Unpredictable, abrupt onset
 - Can recur unpredictably throughout a patient's lifetime
 - Intensity ranges from mild to severe & debilitating
 - Lasts hours to several days

Definitions, cont'd


- Precipitating Factors to vasoocclusive crises:¹
 - Infection
 - Extremes in temperature / weather
 - Dehydration
 - Stress

Epidemiology


- Prevalence of SCD^{1,3}
 - 90,000 – 1000,000 people in the US
 - Most common in people with African heritage
 - Occurs in 1 in 500 African American births
 - Medial survival rates:
 - Age 72 (males)
 - Age 78 (females)
- Vasocclusive Crises^{1,2}
 - Most common reason SCD patients will come to the hospital
 - Almost all patients w/ SCD will have recurrent episodes of acute pain
 - Frequency increases as patients enter early adulthood; peaks between 19-39⁴
 - One of the risk factors for early death in adults w/ SCD


Pathophysiology

Red blood cell



Hemoglobin Molecule (carries Oxygen)





Hemoglobin molecule:


4 AA chains
4 heme molecules

(can carry total of
4 molec. of O_2)

Pathophysiology

- Amino Acid chains in Hemoglobin differ by 1 amino acid


Normal Hbg



Hb in SCD



Makes more
hydrophobic





Pathophysiology


	Normal RBC	Sickled RBC
Hemoglobin Type	HbA	HbS
Solubility when oxygenated	(same)	(same)
Solubility when deoxygenated	---	Reduced (more hydrophobic) -mutant AA chains will cross-link together, forming long chains → polymerization → forms viscous, thick, semi-solid gel that protrudes into RBC membrane → RBC shape becomes distorted
Shape	Bio-concave ("doughnut w/o a hole")	Normal when oxygenated Sickle (crescent) when deoxygenated -But over time, becomes irreversibly sickled due to permanent damage to the cell membrane (phospholipids become permanently rearranged)
Deformability	High Can easily squeeze through capillaries	Low / non-flexible Can clog capillaries (capillary sludging)




Normal hemoglobin


Sickle Cell hemoglobin
forms long, inflexible chainsNORMAL
HEMOGLOBINCLUMPED
HEMOGLOBIN

Cross-section of RBC

Normal
hemoglobin


Cross-section of sickle cell



Abnormal
hemoglobin
form strands
that cause
sickle shape



Pathophysiology


- HbS makes RBC sickled as it is deoxygenated in the capillary bed → sludging → local tissue hypoxia → pain
- The sickling is reversible at first, but ultimately becomes irreversible from permanent damage to RBC membrane





Consequences of Sickling

	Normal RBC	Sickled RBC
Life Span	100-120 days	10-20 days



Clinical Presentation¹

- Deep, throbbing pain
- Local tenderness
- Erythema
- Swelling
- Fever
- Leukocytosis
- Jaundice and increased transaminases if liver is involved
- Increased fibrinogen levels
- Decreased serum pH
- Decreased bicarbonate

Diagnosis¹

- Screening for SCD occurs at birth
- Laboratory findings of SCD
 - Anemia / Low Hbg (7-10 g/dL)
 - Hct 20-30%
 - Increased reticulocytes (immature RBC)
 - Reticulocytosis (3-15%)
 - Increased platelets
 - Increased WBC
 - Blood smear showing sickled forms
 - Markers of hemolysis
 - Increased Lactate Dehydrogenase (from hemolyzed RBC's)
 - Decreased haptoglobin
 - Binds to hemoglobin released during hemolysis
 - Undetectable levels (>7) almost always associated w/ hemolysis

Diagnosis, cont'd

- The acute pain crisis itself more a diagnosis of exclusion
 - No diagnostic test
 - Pain w/o any other explanation
 - Needle aspiration may be needed to r/o osteomyelitis¹
 - Abdominal studies may be needed to r/o other causes of abdominal pain¹
 - Cultures to r/o infectious trigger or cause¹
 - Chest XR to r/o pneumonia, acute chest syndrome
- Laboratory values
 - Non-specific acute phase reactants can be elevated
 - CRP
 - LDH
 - Rhabdomyolysis may be present
 - Elevated CK
 - Muscle ischemia from vasoocclusion → releases muscle contents into circulation → elevated CK
 - Myoglobin also released → nephrotoxic

Goals of Therapy

- Relieve pain²
 - “Severe pain [in SCD acute pain crisis] should be considered a medical emergency that prompts timely and aggressive management.”²
 - Treat aggressively
 - Tailor pain therapy to each patient
 - Consider medications and doses which provided relief during their previous episode
 - Consider medications they were taking at home for pain management
 - Reassess pain frequently
 - Before receiving medications
 - At the peak effect of the medication chosen
 - At frequent intervals
 - Relief could be defined as a reduction in intensity of at least 50-60%
 - Pain assessment tool
 - Choose one; none have been validated for sickle cell pain
 - Monitor for AE of pain medications
 - Opioids: Respiratory depression, sedation, itching, n/v, constipation
- Identify and treat precipitating factors when possible
 - Infx
 - Dehydration
 - Stress

Pharmacological Therapy

- IV Hydration
 - D5W + 1/2NS + 20 mEq KCl/L
 - Adjust for serum chemistry levels
 - Give at no more than 1.5 x maintenance requirement
 - Also consider fluids getting for other drug infusions
- IV Pain Medication
 - Should be started w/in 15-20 mins after arrival in ED²
 - Scheduled pain medication (avoid PRN only)¹
 - Continuous infusion has advantage of less fluctuation in blood levels¹
 - Use boluses or PCA for break-through pain¹
- Blood transfusion if the pt also presents w/ anemia
 - Transfuse to maintain the Hbg level at pt's baseline

Pharmacological Therapy, cont'd

- Suggested pain medications^{1,2}
- If on scheduled and pt experiences break-through pain:¹
 - Give $\frac{1}{4}$ - $\frac{1}{2}$ of the scheduled dose as a bolus q1-2 hrs
 - Assess the amt of rescue doses used in 8-12 hrs and readjust scheduled dose or infusion rate as needed

	mg/Dose	Continuous Infusion (mg/kg/hr)	PCA
Morphine	5-10 q2-4 hr	0.04-0.05 Titrate to effect	Basal: 0.01-0.03 mg/hr Demand: 0.01-0.03 mg/kg q6-10 mins 4-hr lock out: 0.4-0.6 mg/kg
Hydromorphone	1.5-2 q3-4 hr	0.004 Titrate to effect	Basal: 0.003-0.005 mg/kg/hr Demand: 0.03-0.05 mg/kg q6-10 mins 4-hr lock out: 0.06-0.08 mg/kg
Ketorolac	0.5 – 30 q6h **NO MORE THAN 5 DAYS		

Pharmacological Therapy, cont'd

- 3 Approaches to pain management suggested in guidelines:
 - One Approach = Aggressive Approach:
 - Give loading dose (ex: 5-10 mg morphine)
 - Reassess pain in 15-30 mins
 - If no relief, give bolus = $\frac{1}{4}$ - $\frac{1}{2}$ of loading dose given
 - Reassess again in 15-30 mins
 - If no relief, repeat w/ another bolus
 - Once relief is achieved, maintain relief w/ around-the-clock / scheduled dosing
 - Set rescue dose at approx. $\frac{1}{2}$ of maintenance dose for break-through pain
 - Adjust maintenance dose based on number of rescue doses needed

Pharmacological Therapy, cont'd

- Stimulant / Stool Softener
- Antihistamines for itching
- Antiemetics for n/v

Non-pharmacological Therapy

- Prevention³
 - Drink plenty of water
 - Avoid extremes in temperature
 - Avoid areas of low oxygen (mountain climbing, flying)
 - Avoid extremely strenuous exercise
- Hydroxyurea
 - Shown to significantly reduce frequency of acute pain episodes in SCD patients^{1,2}
 - MSH Trial (Multicenter Study of Hydroxyurea in Sickle Cell Anemia)
 - FDA approved for this purpose
 - Indication: frequent painful episodes in SCD
 - Starting dose = 10-15 mg/kg QD (titrate up q8-12 weeks to max tolerated; max=35 mg/kg/day)
 - Takes 3-6 months for effect
 - MOA: induces production of fetal Hb (HbF); has antineoplastic activity (cytotoxic effect in the bone marrow)
 - AE: bone marrow suppression (blood counts must be monitored q2 weeks at first)

References

1. Chan C and Moore R. Sickle Cell Disease. Pharmacotherapy, 8th ed. DiPiro, Talbert, Yee, et al. McGraw-Hill, New York, 2011.
2. National Heart and Lung Institute. The management of sickle cell disease, 4th ed. National Institutes of Health, 2002.
3. Centers for Disease Control and Prevention. www.cdc.gov
4. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: Rates and risk factors. N Eng J Med. 1991; 325(1): 11.
5. Guidelines for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents (2013).
6. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and health-care associated pneumonia. Am J Resp Crit Care Med 2005; 171: 388.